Introduction {#sec1-1}
============

Restless leg syndrome (RLS) is a common disorder characterized by an unpleasant sensation in the legs and a continuous urge to move them. The estimated prevalence of RLS is about 10% in large community-based studies in western industrialized countries.\[[@ref1]\] It has multifactorial etiology and commonly can be drug-induced. As early as 1999, it was reported that olanzapine might cause RLS.\[[@ref2]\] However, since then few similar cases have been recognized which are summarized in [Table 1](#T1){ref-type="table"}. Prescribers need to be cautious regarding this drug-induced condition which can be a possible cause of noncompliance to treatment.

###### 

A review of cases of olanzapine-induced restless leg syndrome reported in literature
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Case Report {#sec1-2}
===========

A 38-year-old married female without any past or family history of psychiatric or neurological illness and with good premorbid functioning. She was harboring delusion of infidelity against her husband along with disturbed socio-occupational and biological functioning for the past 6 years. There was no history of substance use disorders, except excessive caffeine use, or any high risk sexual behavior. Organic psychiatric disorder or symptoms of schizophrenia were not evident. Detailed general physical examination including neurological evaluation did not reveal any abnormality except mild pallor. She reported regular menstruation and the last childbirth was 10 years back. Mental status examination revealed that she was having an uncooperative and aggressive attitude, delusion of infidelity, impaired judgment, and lack of insight. So, she was admitted to psychiatry ward with a diagnosis of persistent delusional disorder as per International Classification of Diseases, 10^th^ edition. She was started on intramuscular olanzapine 10 mg/day. On investigation, her complete hemogram revealed a Hb of 11.5 gms/dL and a serum ferritin level of 30.2 ngm/ml (normal value for females is 10-291 ng/mL). Other routine hematological and biochemical parameters including blood sugar, renal, liver, and thyroid function were within normal limits. We also planned a vitamin B12 and folic acid estimation which could not be done due to lack of resources.

Within 4-5 days of starting olanzapine, there was a decrease in her aggression and she became cooperative for interviewing. However, she would report that she was having sleeping difficulty due to an itching sensation in both upper and lower limbs at night. She would rub her legs against bedclothes, tie pieces of cloth around her limbs, and ask for limb massage to get relief from such a discomfort. She would have such symptoms for hours after lying down at night. During daytime, she would, however, feel comfortable, relaxed, and was able to sleep. She was evaluated for sleep disorder-before this she never had any sleep complaint, neither was there any family history of sleep disorder. During sleep, there was no history of snoring, no abnormal limb or breathing movements. Ear, nose, throat examination was also noncontributory. She was having a thin built and a body mass index of 15.56. As she became cooperative, she was shifted to oral psychotropics (olanzapine 15 mg/day + clonazepam 1 mg at bedtime). Also oral iron supplementation in the form of ferrous fumarate 350 mg, vitamin B12, and ascorbic acid was started. To improve her sleep, general sleep hygiene practices were initiated, she was prohibited from taking any caffeine beverages at night and the clonazepam was further increased up to 2 mg at bedtime. But there was no improvement in her nighttime symptoms.

In view of her above symptoms and investigations, she was diagnosed to have RLS with an International Restless Legs Scale Score (IRLS) of 24 indicating high severity and olanzapine was considered to be the probable cause. Hence, the olanzapine was decreased to 10 mg/day and oral risperidone 2 mg was added at bedtime. On the next day, the severity of symptoms decreased to a RLS score of 12. No other change in medication was done during this period. So, after 2 days, olanzapine was stopped and risperidone was increased to 6 mg at bedtime. Thereafter, her troublesome symptoms ceased completely. Though she still harbored the delusions yet the conviction decreased and she became more cooperative with her husband and the treating clinician. Then after about a week of uneventful ward stay, she was discharged free of her sleep-related difficulties on risperidone 6 mg and clonazepam 1 mg at bedtime with the plan to continue her antipsychotic drugs and iron supplementation on an outpatient basis.

Discussion {#sec1-3}
==========

This patient clearly satisfied all the criteria of RLS as per the International RLS Study Group (IRLSSG), namely, an urge to move the limbs often accompanied by an unpleasant sensation which worsens at rest, inactivity, nighttime, and also this urge is partially or completely relieved by movement.\[[@ref7]\] Before a diagnosis of RLS in this patient, we considered its differential diagnosis-being uncooperative due to psychotic state, akathisia, psychogenic cause, and peripheral neuropathy. Lack of symptoms during daytime and a zero score on the Barnes Akathisia Rating Scale ruled out akathisia. The classical presentation and diurnal variation clinched the diagnosis as RLS can be adequately diagnosed by the IRLSSG criteria alone. Sleep laboratory observation could not be done due to lack of this facility in our setup. For a diagnosis of RLS, tests like polysomnography or "suggested immobilisation test" lack reliability and are only suitable for special circumstances.\[[@ref8]\] Polysomnography would have been useful in ruling out comorbid periodic limb movement disorder or sleep disordered breathing. The fact that her symptoms persisted even with change of mode of delivery of olanzapine from injectable to oral, the temporal association of symptoms with increasing doses of olanzapine and a high score of +8 on Naranjo Adverse Drug Reaction Probability Scale makes the association of this adverse drug reaction (ADR) with olanzapine highly probable.\[[@ref9]\]

The probable reason for RLS was evaluated. Lack of a family history ruled out genetic influences as etiology. Among the major secondary causes of RLS, a relatively low ferritin level (\<50 μg/dL) may provide a probable answer as it has been shown that low brain iron leads to altered dopamine metabolism and D2 receptor profile states particularly in substantia nigra and putamen. Other common causes of RLS like parkinsonism, renal failure, and diabetes mellitus were also considered. These were ruled out by physical examination and biochemical investigations. Considering other confounding factors, our case scored 14 points which is better than the minimum score of 10 considered by Hoques *et al*., in his comprehensive review.\[[@ref10]\]

One hypothesis regarding the cause of RLS is thought to be dysfunction of dopaminergic innervations of the spinal cord.\[[@ref11]\] In this regard, it is also interesting to note that though the patient had symptoms on olanzapine, yet she reported no symptoms with risperidone which also has significant anti-dopaminergic activity. As illustrated in [Table 1](#T1){ref-type="table"}, only two prior cases have been reported where RLS induced by olanzapine was relieved by an antipsychotic with more dopamine antagonist activity like amisulpride-haloperidol combination and risperidone, respectively. This calls for an investigation into the underlying mechanism other than dopamine dysfunction.

Our case had another special characteristic that requires attention-the presence of symptoms in upper limbs. Though such a presentation is common in patients with RLS and even exclusive upper limb variant has been described, yet upper limb involvemnet is a rare manifestation in drug induced variant of RLS.\[[@ref12]\] Only one such previous case has been described.\[[@ref3]\] This case calls for vigilance by clinicians while prescribing olanzapine, considering the fact that it is a commonly prescribed antipsychotic drug in India.
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